The Embrace Journalism Award recognizes accurate and responsible reporting on urinary incontinence. Journalists from around the world were honored for their articles on this debilitating condition, which affects one in every three women at some time in their lives.
The five-year data demonstrate long-term efficacy and reliability of MAL-PDT for treating superficial and nodular basal cell carcinomas, with superior cosmesis compared to cryotherapy. The treatment was found to be non-inferior to surgery in relation to initial response rates, but with significantly better cosmetic outcomes.
The global survey found that 26% of respondents never disclose their bipolar disorder due to social stigma, while 71% believe the public does not understand their illness. The survey also revealed that successful treatment would lead to significant quality of life changes.
A new survey suggests that Seroquel provides significant quality of life improvements for bipolar patients, with 79% believing a successful treatment would lead to increased functionality and improved lifestyle. The medication has been shown to effectively manage symptoms of depression and anxiety in rapid-cycling patients.
Studies show SEROQUEL reduces suicidal thinking in bipolar depression, improves quality of life, and enhances treatment adherence. Improved compliance with medication is also a significant benefit.
SEROQUEL demonstrates a higher compliance rate compared to risperidone and olanzapine, with significant improvements in cognitive function, including working and verbal memory, while also offering a superior side effect profile.
A study found that Seroquel significantly reduced symptoms of agitation in elderly patients with Alzheimer's disease, improving their quality of life. The treatment was well-tolerated, with no decline in cognitive function observed.
Crestor demonstrates improved lipid profiles and lower LDL-C targets than atorvastatin, achieving higher patient success rates with fewer doses. Crestor also shows effectiveness in reducing apolipoprotein B levels and improving the Apo B:Apo A-I ratio.
A new study reveals that 8 out of 10 patients with serious mental illnesses are satisfied with their Seroquel treatment, experiencing improved positive and negative symptoms. This is attributed to its effectiveness and favorable side effect profile, leading to better compliance and outcomes.
A new study found Seroquel to be effective in rapidly relieving core symptoms of depression, such as sadness and suicidal thoughts, in patients with rapid-cycling bipolar disorder. The treatment was also well-tolerated, with a low risk of mania compared to other treatments.
A recent study demonstrated that SPIRIVA significantly reduces COPD exacerbations, improving patient quality of life and reducing healthcare costs. The medication also prolongs the time to first exacerbation and significantly lowers health resource utilization.
A recent study found that over half of patients with COPD are incorrectly diagnosed with asthma, leading to delayed treatment. The study suggests that simple symptom-based diagnostic questions can improve diagnosis rates and improve patient outcomes.
The studies confirm SEROQUEL's effectiveness across a range of schizophrenia symptoms, including positive and negative symptoms, and cognitive functioning. Cognitive improvements were seen in patients treated with SEROQUEL.
The BOLDER trial found SEROQUEL significantly reduces anxiety symptoms in bipolar depression patients within the first week of treatment. It also improves depressive symptoms and is well-tolerated with a favorable side effect profile.
A new study demonstrates that Xeloda reduces the risk of colon cancer recurrence (relapse-free survival) by 14% compared to i.v. 5-FU/LV after surgery. The global trial, X-ACT, met its primary endpoint and offers new hope for patients with early stage colon cancer.
Over 60% of type 2 diabetes patients fail to meet recommended glucose treatment goals, increasing risk of complications such as heart disease and blindness. The Control to Goal initiative aims to bridge the gap between guidelines and clinical practice, promoting better diabetes management.
A one-year study involving 539 adolescents aged 12 to 16 found that Xenical significantly reduced fat mass, waist circumference, and BMI compared to lifestyle changes alone. The medication was well-tolerated, with similar adverse events reported as in adults.
A new study shows that Seroquel achieves remission in bipolar mania, with a significant increase in remission rates over time. The medication has been shown to be effective in reducing symptoms of racing thoughts, reckless behavior, and decreased sleep.
The BOLDER study found SEROQUEL to be superior to placebo in reducing depressive symptoms and anxiety in patients with bipolar disorder. Approximately 50% of patients achieved remission from their bipolar depression symptoms.
A new study shows that preoperative anastrozole treatment can downstage tumors and allow more patients to undergo less extensive breast-conserving surgery, reducing the need for mastectomy. The treatment has been shown to be effective in improving outcomes for postmenopausal women with hormone receptor-positive breast cancer.
Faslodex, a novel oestrogen receptor antagonist, has been approved by the EU for treating advanced oestrogen receptor-positive breast cancer. The drug offers durable responses and tolerability benefits compared to existing therapies, with a unique sustained release formulation administered monthly.
Crestor effectively tackles elevated non-HDL cholesterol levels, a key risk factor for heart attacks and strokes, in patients with metabolic syndrome. The medication demonstrates significant results in reducing the incidence of these cardiovascular diseases.
A two-year study found that quetiapine treatment resulted in statistically significant improvements in positive, negative and depressive symptoms. Patients also showed notable enhancements in quality of life, with minimal reported side effects.
The XENDOS study found that Xenical significantly reduces the risk of developing type 2 diabetes by 37% compared to lifestyle changes alone and 52% in patients with impaired glucose tolerance. The medication also produces greater long-term weight loss and improves cardiovascular risk factors.
The STELLAR and MERCURY I studies show CRESTOR significantly improves key apolipoprotein and lipid ratios, including Apo B, Apo A-I, and the Apo B:Apo A-I ratio, in patients with hypercholesterolaemia. These findings support CRESTOR's benefits in reducing cardiovascular disease risk.
Researchers are evaluating the effects of CRESTOR on atherosclerosis using cutting-edge imaging technologies like IVUS and MRI. The goal is to slow or even reverse the progression of this silent killer disease, which can lead to heart attacks and strokes.
A new study found that Neoral is as effective as tacrolimus in preventing acute rejection but better tolerated, with lower rates of diabetes and diarrhoea. The study analyzed 499 patients and showed significant differences in tolerability between the two immunosuppressive therapies.
Seroquel was shown to significantly reduce mean Young Mania Rating Scale (YMRS) total scores in patients with bipolar disorder, with a faster reduction in symptoms compared to placebo. The medication was well-tolerated and had fewer side effects than other treatments like haloperidol.
A major study of over 7,000 living donor kidney transplant patients found that Neoral significantly improves three-year graft survival rates and prolongs the estimated graft half-life compared to tacrolimus. This suggests a clear advantage for Neoral in reducing the risk of transplant failure.
The XENDOS study shows that Xenical significantly improves weight loss, waist measurement, blood pressure, triglyceride levels, fasting plasma glucose, and HDL cholesterol in patients with Metabolic Syndrome. The treatment also reduces the risk of type 2 diabetes by 36%.
The guidelines recommend close monitoring of modifiable risk factors like obesity and immunosuppressive therapy, as well as careful selection of immunosuppressive agents. Effective management can reduce patient numbers affected and ensure long-term success of the transplant, maintaining quality of life and reducing healthcare costs.
Quetiapine has been shown to be statistically more effective at treating manic symptoms of bipolar disorder than placebo. The results of the clinical trials indicate rapid symptom improvement from day four and a favorable side effect profile, making it an exciting development in psychiatry.
The American Psychiatric Association and AstraZeneca have launched an international awards programme to support young psychiatry researchers working in the fields of bipolar disorder and schizophrenia. The programme aims to provide vital career development support to help advance innovative research and treatment options for patients.
Certican has been shown to target underlying causes of chronic allograft dysfunction and late graft loss, including acute rejection and vascular remodelling. The drug demonstrated superiority over azathioprine in reducing acute rejection episodes and pulmonary function decline.
A study found that patients with schizophrenia experienced improved symptom management and reduced side effects when switching to Seroquel, including significant reductions in Positive and Negative Syndrome Scale scores and Clinical Global Impression Severity of Illness ratings.
AstraZeneca has submitted an application to the European Health Authorities for a new indication for Seroquel in treating manic episodes associated with bipolar disorder. The company's clinical trial programme showed strong and positive results, confirming Seroquel as an ideal first-line agent for this condition.
Quetiapine has delivered strong and positive results in treating acute mania associated with bipolar disorder, confirming its potential as an ideal first-line therapy. The medication also showed improved quality of life by minimizing side effects, making it a valuable treatment option for patients.
A new generation antipsychotic quetiapine, combined with mood stabilizers, shows improved efficacy in treating manic symptoms of bipolar disorder. The study results indicate that more patients experience full resolution of manic symptoms when treated with quetiapine.
The XENDOS study found that 28.3% of obese individuals had undetected or untreated diabetes or pre-diabetes. Xenical-treated patients experienced significant weight loss and improved cardiovascular risk factors compared to lifestyle intervention alone.
The XENDOS study demonstrates that Xenical plus lifestyle intervention is more effective than lifestyle intervention alone in preventing or delaying the development of type 2 diabetes. Significant and sustained weight loss was achieved with Xenical, which also improved cardiovascular risk factors.
Recent studies have shown that combining Xenical with a mildly reduced calorie diet can improve glycaemic control, body weight, and waist circumference in overweight or obese patients with type 2 diabetes. The medication has been found to reduce HbA1c levels by as much as 46% in patients with poor glycaemic control.
Researchers found Xenical significantly improved HbA1c and fasting plasma glucose levels in patients with type 2 diabetes. Additionally, treatment with Xenical showed post-prandial glucose benefits and cost-effectiveness as an adjunctive therapy to oral anti-diabetic medications.
A 12-month study of 430 overweight men and women showed a significant weight loss of 11.6 kg with Xenical, with improvements in blood pressure, cholesterol levels, and waist circumference. The results demonstrate the efficacy of Xenical in a real-life clinical practice setting.
Three exceptional researchers have been awarded the Young Minds in CNS Award for their innovative work on residual symptoms in bipolar disorder, serotonin receptors in anxiety disorders, and thalamic neurochemistry in schizophrenia. The $20,000 award will support career development and attendance at international congresses.
A study presented at Nutrition Week showed that patients taking weight loss medication Xenical who enrolled in a support programme lost twice as much weight as those who did not (8.5kg vs 4kg). The two-way support improved patient satisfaction, with over 90% of patients worldwide satisfied with their treatment and level of weight loss.
The AstraZeneca CNS Awards Program was launched in 2002 to support the career advancement of young physicians in central nervous system (CNS) fields. The program recognizes excellence in innovative research, educational efforts, travel, and materials, and offers a platform for award winners to reach their full potential.